Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined CABG and Stem-Cell Transplantation for Heart Failure
NCT00418418Phase 2Unknown
- Sponsor
- University of Helsinki
- Start
- Oct 2006
- Primary completion
- Dec 2009
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mesenchymal stem cells in heart failure (HF), coronary artery disease (CAD) and myocardial infarction (MI), sponsored by University of Helsinki. Primary endpoint: Ejection Fraction at 1 year. Status: unknown.
02
Drugs
mesenchymal stem cells
03
Conditions
heart failure (HF)coronary artery disease (CAD)myocardial infarction (MI)
Beyond the preview
Go deeper on NCT00418418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00418418.